Drug Approval | December 25, 2023
Eugia's East Windsor facility gets 10 observations from USFDA
The plant is yet to start commercial operations
The plant is yet to start commercial operations
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The product will be manufactured at Lupin’s Nagpur facility in India
Phase 3 data expected in the second half of 2024
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Subscribe To Our Newsletter & Stay Updated
